Semaglutide in India: the paediatric gap

A letter published in Indian Pediatrics on 20 July 2026 asks a question the GLP-1 access debate has largely skipped: now that generic semaglutide is available in India at a fraction of the innovator price, what does that mean for children and special populations^[1]? The author, Debabrata Mohapatra of Vardhman Mahavir Medical College and Safdarjung Hospital in New Delhi, frames the rollout as an opportunity and raises the gaps that make expanded access complicated for non-adult and non-standard patients.

What changed on the supply side

India's patent landscape shifted in 2025 and 2026 when several domestic pharmaceutical companies launched their own semaglutide formulations. Phase III non-inferiority data now exists for multiple manufacturers. Sun Pharmaceutical Industries demonstrated non-inferior glycaemic efficacy versus the reference Ozempic in a 314-patient Indian trial (HbA1c reduction of 2.04% test versus 1.95% reference at 24 weeks; difference of -0.09%, 95% CI -0.26% to 0.09%)^[2]. Alkem Laboratories published the SIZE-DM study, a 23-centre Indian trial in which generic semaglutide produced non-inferior HbA1c reductions of approximately 2.2% over 24 weeks, with 86.62% of participants reaching targets below 7.0%^[3]. Zydus Lifesciences completed a 24-week weight-management non-inferiority trial showing approximately 11% body-weight reduction, meeting the prespecified margin^[4].

Three separate datasets from three separate Indian manufacturers, all in adult populations, all showing non-inferiority to the reference product. That evidence base is what makes domestic availability credible as a policy matter, not just a commercial one. Whether a generic is genuinely interchangeable in practice depends on formulation, cold-chain reliability, device handling, and prescriber familiarity, but the pharmacological non-inferiority case has been made.

What the adolescent evidence already shows

The reference point for paediatric use is STEP TEENS, the Weghuber et al. double-blind, placebo-controlled trial in 201 adolescents aged 12 to 17 with obesity, published in the New England Journal of Medicine in December 2022^[5]. The primary outcome was a mean BMI change of -16.1% with semaglutide 2.4 mg weekly versus +0.6% on placebo at 68 weeks, a difference of -16.7 percentage points (95% CI -20.3 to -13.2; P<0.001). Seventy-three percent of the semaglutide group achieved at least 5% weight reduction, compared with 18% on placebo. Gastrointestinal adverse events occurred in 62% of the treatment group versus 42% on placebo.

STEP TEENS underpinned the FDA approval of Wegovy for adolescents aged 12 and above in December 2022. It is the strongest available controlled evidence for this age group. What it does not answer is how well any of the Indian generic formulations would perform in Indian adolescent populations, which differ in diet, comorbidity profile, baseline body-composition norms, and access to the structured lifestyle support that was part of the trial protocol.

The unanswered questions Mohapatra identifies

The 2026 letter flags several categories of uncertainty that the adult non-inferiority trials cannot resolve.

First, oral semaglutide. Phase 3 trials for oral semaglutide in youth with type 2 diabetes are underway, but peer-reviewed results are not yet published at the time the letter was written. Oral formulations may matter more for adolescents than for adults, because injection aversion and needle phobia are disproportionately common in younger patients and affect adherence in ways not captured in short-duration trials.

Second, disordered eating. Mohapatra's own earlier research in 180 Indian adolescents found that disordered eating behaviours affected 17.2% of participants, body dissatisfaction was present in 81.1%, and females showed 7.89 times higher odds of disordered eating than males^[6]. Semaglutide's appetite-suppressive mechanism and its marketing context (weight loss as the primary outcome) creates specific risks in populations already showing high rates of body dissatisfaction. How prescribers screen for and monitor disordered eating before and during treatment is not standardised in the Indian paediatric context.

Third, special populations. Adolescents with type 1 diabetes, those with chronic kidney disease, and those on drugs that interact with GLP-1 receptor agonists are populations in whom the adult non-inferiority data provides little direct guidance. Dosing, monitoring, and endpoints may need adjustment, and Indian paediatric prescribers working in resource-limited settings may not have ready access to specialist oversight.

What affordable access does and does not solve

Price reduction matters. The innovation-era cost of semaglutide placed it out of reach for most Indian patients outside private referral centres. If generic formulations reach pharmacies at a price point accessible to middle-income households, the population of patients who can realistically start treatment grows substantially.

But access is not the same as appropriateness. The adult non-inferiority trials confirm that the generic molecule works in adults. They do not tell prescribers how to use the molecule in a 13-year-old with obesity and disordered eating, or a 16-year-old with type 2 diabetes and anaemia, or an adolescent in a district hospital without the dietetic support that was built into STEP TEENS. Those questions require paediatric-specific evidence and paediatric-specific guidance, neither of which the current Indian regulatory and clinical infrastructure has fully produced.

What paediatricians and families should take from this

The letter is a call for the Indian paediatric community to engage proactively with semaglutide access before prescribing norms are set by default. That means generating Indian adolescent data, developing screening protocols for disordered eating, and working out monitoring pathways for the special populations the adult trials excluded. Families reading about affordable generic semaglutide in India should understand that adult availability does not automatically translate to paediatric appropriateness, and that a conversation with a paediatrician or adolescent medicine specialist is the correct starting point.

This article is for educational purposes and does not constitute medical advice. Any decision about starting, continuing, or adjusting semaglutide in a child or adolescent belongs with the treating clinician who knows the individual case. Consult a qualified healthcare professional before acting on anything you read here.